Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir von Schnell, Gretja, Tripathi, Rakesh, Krishnan, Preethi, Beyer, Jill, Reisch, Thomas, Irvin, Michelle, Dekhtyar, Tatyana, Setze, Carolyn, Rodrigues‐Jr, Lino, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Chayama, Kazuaki, Kumada, Hiromitsu, Collins, Christine, Pilot‐Matias, Tami

Volltext

Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects von Zha, Jiuhong, PhD, Badri, Prajakta S., PhD, Ding, Bifeng, MS, Uchiyama, Naotaka, PhD, Alves, Katia, MD, Rodrigues-Jr, Lino, MD, Redman, Rebecca, MD, Dutta, Sandeep, PhD, Menon, Rajeev M., PhD

Volltext

Incidence of fibrosing colonopathy with pancreatic enzyme replacement therapy in patients with cystic fibrosis von Chiuve, Stephanie E, Fife, Daniel, Leitz, Gerhard, Peterson, Craig, Campbell, Neil M, Rennig, Amanda, Rodrigues, Jr, Lino, Decktor, Dennis, Dowd, Christopher, Marshall, Bruce C, Borowitz, Drucy

Volltext

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir von Krishnan, Preethi, Schnell, Gretja, Tripathi, Rakesh, Beyer, Jill, Reisch, Thomas, Zhang, Xinyan, Setze, Carolyn, Rodrigues, Jr, Lino, Burroughs, Margaret, Redman, Rebecca, Chayama, Kazuaki, Kumada, Hiromitsu, Collins, Christine, Pilot-Matias, Tami

Volltext

Helicobacter pylori eradication does not influence gastroesophageal reflux disease: a prospective, parallel, randomized, open-label, controlled trial von Rodrigues, Jr, Lino, Faria, Cintya Miler de, Geocze, Stephan, Chehter, Luiz

Volltext

日本人高齢ジェノタイプ1b型C型肝炎ウイルス感染患者におけるオムビタスビル/パリタプレビル/リトナビルの安全性および有効性―GIFT-I試験の事後解析... von 茶山, 一彰, 狩野, 吉康, Rodrigues-Jr, Lino, Burroughs, Margaret H., 熊田, 博光

Volltext

Safety and efficacy of ombitasvir/paritaprevir/ritonavir in genotype 1b-infected elderly Japanese patients in the GIFT-I study von Chayama, Kazuaki, Karino, Yoshiyasu, Rodrigues, Lino, Jr, Burroughs, Margaret H, Pilot-Matias, Tami, Zhang, Xinyan, Kapoor, Mudra, Kumada, Hiromitsu

Volltext

ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b In... von Andreone, Pietro, Colombo, Massimo G, Enejosa, Jeffrey V, Koksal, Iftihar, Ferenci, Peter, Maieron, Andreas, Müllhaupt, Beat, Horsmans, Yves, Weiland, Ola, Reesink, Henk W, Rodrigues, Lino, Hu, Yiran B, Podsadecki, Thomas, Bernstein, Barry

Volltext

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis von Kumada, Hiromitsu, Chayama, Kazuaki, Rodrigues, Lino, Suzuki, Fumitaka, Ikeda, Kenji, Toyoda, Hidenori, Sato, Ken, Karino, Yoshiyasu, Matsuzaki, Yasushi, Kioka, Kiyohide, Setze, Carolyn, Pilot‐Matias, Tami, Patwardhan, Meenal, Vilchez, Regis A., Burroughs, Margaret, Redman, Rebecca

Volltext

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection von Wyles, David, Weiland, Ola, Yao, Betty, Weilert, Frank, Dufour, Jean-Francois, Gordon, Stuart C., Stoehr, Albrecht, Brown, Ashley, Mauss, Stefan, Zhang, Zhenzhen, Pilot-Matias, Tami, Rodrigues, Lino, Mensa, Federico J, Poordad, Fred

Volltext

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients von Chayama, Kazuaki, Notsumata, Kazuo, Kurosaki, Masayuki, Sato, Ken, Rodrigues, Lino, Setze, Carolyn, Badri, Prajakta, Pilot‐Matias, Tami, Vilchez, Regis A., Kumada, Hiromitsu

Volltext

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection von Zuckerman, Eli, Gutierrez, Julio A., Dylla, Douglas E., de Ledinghen, Victor, Muir, Andrew J., Gschwantler, Michael, Puoti, Massimo, Caruntu, Florin, Slim, Jihad, Nevens, Frederik, Sigal, Samuel, Cohen, Stanley, Fredrick, Linda M., Pires dos Santos, Ana Gabriela, Rodrigues, Lino, Dillon, John F.

Volltext

Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment von Khatri, Amit, Dutta, Sandeep, Marbury, Thomas C., Preston, Richard A., Rodrigues, Lino, Wang, Haoyu, Awni, Walid M., Menon, Rajeev M.

Volltext

Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection von Lawitz, Eric, Sullivan, Greg, Rodriguez-Torres, Maribel, Bennett, Michael, Poordad, Fred, Kapoor, Mudra, Badri, Prajakta, Campbell, Andrew, Rodrigues, Lino, Hu, Yiran, Pilot-Matias, Tami, Vilchez, Regis A

Volltext

Integrated efficacy and safety analysis of GT1-6 treatment-naive, non-cirrhotic and compensated cirrhotic patients who received 8 weeks of glecaprevir/pibrentasvir von Zuckerman, Eli, Gutierrez, Julio, Dylla, Doug, de Lédinghen, Victor, Muir, Andrew, Gschwantler, Michael, Puoti, Massimo, Slim, Jihad, Nevens, Frederik, Fredrick, Linda, dos Santos, Ana Gabriela Pires, Rodrigues, Jr, Lino, Dillon, John

Volltext

THU406 - Integrated efficacy and safety analysis of GT1-6 treatment-naive, non-cirrhotic and compensated cirrhotic patients who received 8 weeks of glecaprevir/pibrentasvir von Zuckerman, Eli, Gutierrez, Julio, Dylla, Doug, de Lédinghen, Victor, Muir, Andrew, Gschwantler, Michael, Puoti, Massimo, Slim, Jihad, Nevens, Frederik, Fredrick, Linda, dos Santos, Ana Gabriela Pires, Rodrigues, Jr, Lino, Dillon, John

Volltext

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients von Sato, Ken, Chayama, Kazuaki, Alves, Katia, Toyoda, Hidenori, Suzuki, Fumitaka, Kato, Koji, Rodrigues, Lino, Zhang, Xinyan, Setze, Carolyn, Pilot-Matias, Tami, Burroughs, Margaret, Redman, Rebecca, Kumada, Hiromitsu

Volltext

Effect of co-medications on paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin pharmacokinetics: analysis of data from seven Phase II/III trials von Polepally, Akshanth R, Badri, Prajakta S, Parikh, Apurvasena, Rodrigues, Jr, Lino, Da Silva-Tillmann, Barbara A, Mensing, Sven, Podsadecki, Thomas J, Awni, Walid M, Dutta, Sandeep, Menon, Rajeev M

Volltext

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b in... von Andreone, Pietro, Colombo, Massimo G, Enejosa, Jeffrey V, Koksal, Iftihar, Ferenci, Peter, Maieron, Andreas, Müllhaupt, Beat, Horsmans, Yves, Weiland, Ola, Reesink, Henk W, Rodrigues Jr, Lino, Hu, Yiran B, Podsadecki, Thomas, Bernstein, Barry

Volltext

929e PEARL-II: Randomized Phase 3 Trial of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333 With or Without Ribavirin in Hepatitis C Virus Genotype 1b-Infected, Treat... von Andreone, Pietro, Colombo, Massimo, Enejosa, Jeffrey V, Koksal, Iftihar, Ferenci, Peter, Maieron, Andreas, Müllhaupt, Beat, Horsmans, Yves, Weiland, Ola, Reesink, Henk W, Jr, Lino Rodrigues, Hu, Yiran B, Podsadecki, Thomas

Volltext